Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for treatment of COVID-19
IRCT20201024049134N3Phase 3Completed
- Sponsor
- Babol University of Medical Sciences
- Start
- Jun 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of colchicine in coronavirus disease 2019 (COVID-19), sponsored by Babol University of Medical Sciences. Started Jun 2021; status: completed.
02
Drugs
colchicine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20201024049134N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201024049134N3.